Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Salvage Nivolumab + Ipilimumab in Advanced RCC
NCT03117309Phase 2Completed
- Start
- Apr 2017
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in renal cell carcinoma (RCC). Started Apr 2017; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03117309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117309.